Skip to main content
Erschienen in: Tumor Biology 6/2011

01.12.2011 | Research Article

Effect of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry on identifying biomarkers of laryngeal carcinoma

verfasst von: Chibo Liu, Chunqin Pan, Haibao Wang, Liang Yong

Erschienen in: Tumor Biology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim is to study the serum protein fingerprint of patients with laryngeal carcinoma (LC) and to screen for protein molecules closely related to LC during the onset and progression of the disease with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Serum samples from 68 patients with LC and 117 non-cancer control samples (75 healthy volunteers and 42 Vocal fold polyps). Q10 protein chips and PBSII-C protein chips reader (Ciphergen Biosystems Inc.) were used. The protein fingerprint expression of all the Serum samples and the resulting profiles between cancer and non-cancer groups were analyzed with Biomarker Wizard system. A group of proteomic peaks were detected. Three differently expressed potential biomarkers were identified with the relative molecular weights of 5,915, 6,440 and 9,190 Da. Among the three peaks, the one with m/z 6,440 was down-regulated, and the other two peaks with m/z 5,915 and 9,190 were up-regulated in LC. This diagnostic model could distinguish LC patients from controls with a sensitivity of 92.1% and a specificity of 91.9%. Moreover, blind test data showed a sensitivity of 86.7% and a specificity of 89.1%. The data suggested that SELDI technology could be used to screen proteins with altered expression levels in the serum of LC patients. These protein peaks were considered as specific serum biomarkers of LC and have the potential value for further investigation.
Literatur
1.
Zurück zum Zitat Nadal A, Cardesa A. Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch. 2003;442:1–7.PubMed Nadal A, Cardesa A. Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch. 2003;442:1–7.PubMed
2.
Zurück zum Zitat Sanderson RJ, Ironside JAD. Squamous cell carcinoma of the head and neck. BMJ. 2002;325:822–7.PubMedCrossRef Sanderson RJ, Ironside JAD. Squamous cell carcinoma of the head and neck. BMJ. 2002;325:822–7.PubMedCrossRef
3.
Zurück zum Zitat Sasaki C, Jassin B. Cancer of the pharynx and larynx. Am J Med. 2001;111:119S–23S.CrossRef Sasaki C, Jassin B. Cancer of the pharynx and larynx. Am J Med. 2001;111:119S–23S.CrossRef
4.
Zurück zum Zitat Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148–55.PubMed Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148–55.PubMed
5.
Zurück zum Zitat Liu CB, Liang Y, Pan CQ, Wang HB, Mou SH. Proteome study of differential protein expression in HBV-related primary hepatic carcinoma. Chem J Chin Univ. 2009;30:1763–6. Liu CB, Liang Y, Pan CQ, Wang HB, Mou SH. Proteome study of differential protein expression in HBV-related primary hepatic carcinoma. Chem J Chin Univ. 2009;30:1763–6.
6.
Zurück zum Zitat Høgdall E, Fung ET, Christensen IJ, Yip C, Nedergaard L, et al. Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin Appl. 2010;4:940–52.PubMedCrossRef Høgdall E, Fung ET, Christensen IJ, Yip C, Nedergaard L, et al. Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin Appl. 2010;4:940–52.PubMedCrossRef
7.
Zurück zum Zitat Liu C, Shen J, Pan C, Yang L, Mou S, Wang H, et al. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol. 2010;134:235–41.PubMedCrossRef Liu C, Shen J, Pan C, Yang L, Mou S, Wang H, et al. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol. 2010;134:235–41.PubMedCrossRef
8.
Zurück zum Zitat Cho WC, Yip TT, Ngan RK, Yip TT, Podust VN, Yip C, et al. ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin Chem. 2007;53:241–50.PubMedCrossRef Cho WC, Yip TT, Ngan RK, Yip TT, Podust VN, Yip C, et al. ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin Chem. 2007;53:241–50.PubMedCrossRef
9.
Zurück zum Zitat Liu C, Wang H, Pan C, Liang Y. Serum protein fingerprint of patients with gastric cancer by SELDI technology. Afr J Biotechnol. 2010;9(15):2298–304. Liu C, Wang H, Pan C, Liang Y. Serum protein fingerprint of patients with gastric cancer by SELDI technology. Afr J Biotechnol. 2010;9(15):2298–304.
10.
Zurück zum Zitat Liu C, Pan C, Shen J, Wang H, Yong L. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci. 2011;8:39–47.PubMed Liu C, Pan C, Shen J, Wang H, Yong L. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci. 2011;8:39–47.PubMed
11.
Zurück zum Zitat Franchin G, Minatel E, Gobitti C, Talamini R, Vaccher E, Sartor G, et al. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients. Cancer. 2003;98:765–72.PubMedCrossRef Franchin G, Minatel E, Gobitti C, Talamini R, Vaccher E, Sartor G, et al. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients. Cancer. 2003;98:765–72.PubMedCrossRef
12.
13.
Zurück zum Zitat Liu C. The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol. 2011; Article ID 245821. Liu C. The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol. 2011; Article ID 245821.
14.
Zurück zum Zitat Xiao X, Zhao X, Liu J, Guo F, Liu D, He D. Discovery of laryngeal carcinoma by serum proteomic pattern analysis. Sci China C Life Sci. 2004;47:219–23.PubMed Xiao X, Zhao X, Liu J, Guo F, Liu D, He D. Discovery of laryngeal carcinoma by serum proteomic pattern analysis. Sci China C Life Sci. 2004;47:219–23.PubMed
15.
Zurück zum Zitat Zhang X, Chen Y, Wang J, Qu X, Deng B, Wang J, et al. Application of SELDI-TOF MS technology analyzing serum protein profiling for distinguishing laryngeal carcinoma from ordinary people. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006;20:842–6.PubMed Zhang X, Chen Y, Wang J, Qu X, Deng B, Wang J, et al. Application of SELDI-TOF MS technology analyzing serum protein profiling for distinguishing laryngeal carcinoma from ordinary people. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006;20:842–6.PubMed
16.
Zurück zum Zitat Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, et al. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem. 2006;52:421–9.PubMedCrossRef Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, et al. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem. 2006;52:421–9.PubMedCrossRef
17.
Zurück zum Zitat Liang Y, Fang M, Li J, Liu CB, Rudd JA, Kung HF, et al. Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol. 2006;81:176–80.PubMedCrossRef Liang Y, Fang M, Li J, Liu CB, Rudd JA, Kung HF, et al. Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol. 2006;81:176–80.PubMedCrossRef
18.
Zurück zum Zitat Zhang Q, Wang J, Dong R, Yang S, Zheng S. Identification of novel serum biomarkers in child nephroblastoma using proteomics technology. Mol Biol Rep. 2011;38:631–8.PubMedCrossRef Zhang Q, Wang J, Dong R, Yang S, Zheng S. Identification of novel serum biomarkers in child nephroblastoma using proteomics technology. Mol Biol Rep. 2011;38:631–8.PubMedCrossRef
19.
Zurück zum Zitat Fan Y, Shi L, Liu Q, Dong R, Zhang Q, Yang S, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer. 2009;8:79.PubMedCrossRef Fan Y, Shi L, Liu Q, Dong R, Zhang Q, Yang S, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer. 2009;8:79.PubMedCrossRef
20.
Zurück zum Zitat Hellgren G, Andersson B, Nierop AF, Dahlgren J, Hochberg Z, Albertsson-Wikland K. A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature. Proteome Sci. 2008;6:35.PubMedCrossRef Hellgren G, Andersson B, Nierop AF, Dahlgren J, Hochberg Z, Albertsson-Wikland K. A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature. Proteome Sci. 2008;6:35.PubMedCrossRef
21.
Zurück zum Zitat Rai AJ, Zhang Z, Rosenzweig J, Shih IEM, Pham T, Fung ET, et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med. 2002;126:1518–26.PubMed Rai AJ, Zhang Z, Rosenzweig J, Shih IEM, Pham T, Fung ET, et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med. 2002;126:1518–26.PubMed
22.
Zurück zum Zitat Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 2003;9:2904–11.PubMed Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 2003;9:2904–11.PubMed
23.
Zurück zum Zitat Cho WC. Proteomics technologies and challenges. Genom Proteomics Bioinf. 2007;5:77–85.CrossRef Cho WC. Proteomics technologies and challenges. Genom Proteomics Bioinf. 2007;5:77–85.CrossRef
24.
Zurück zum Zitat Silbiger VN, Luchessi AD, Hirata RD, Neto LG, Pastorelli CP, Ueda EK, et al. Time course proteomic profiling of human myocardial infarction plasma samples: an approach to new biomarker discovery. Clin Chim Acta. 2011;412:1086–93.PubMedCrossRef Silbiger VN, Luchessi AD, Hirata RD, Neto LG, Pastorelli CP, Ueda EK, et al. Time course proteomic profiling of human myocardial infarction plasma samples: an approach to new biomarker discovery. Clin Chim Acta. 2011;412:1086–93.PubMedCrossRef
25.
Zurück zum Zitat Cho WC, Cheng CH. Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics. 2007;4:401–10.PubMedCrossRef Cho WC, Cheng CH. Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics. 2007;4:401–10.PubMedCrossRef
26.
Zurück zum Zitat Cho WC. Research progress in SELDI-TOF-MS and its clinical applications. Sheng Wu Gong Cheng Xue Bao. 2006;22:871–6.PubMed Cho WC. Research progress in SELDI-TOF-MS and its clinical applications. Sheng Wu Gong Cheng Xue Bao. 2006;22:871–6.PubMed
27.
Zurück zum Zitat Xu Y, Qiao S, Huangfu H, Wang B. Analysis of proteomic spectra in serum from patients with laryngeal carcinoma by SELDI-TOF-MS technology. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;23:1116–9.PubMed Xu Y, Qiao S, Huangfu H, Wang B. Analysis of proteomic spectra in serum from patients with laryngeal carcinoma by SELDI-TOF-MS technology. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;23:1116–9.PubMed
28.
Zurück zum Zitat Cheng L, Zhou L, Tao L, Zhang M, Cui J, Liu Y. Preliminary study of proteomic shift from normal to premalignant laryngeal lesions and to laryngeal squamous cell carcinoma. Acta Otolaryngol. 2009;129:774–8.PubMedCrossRef Cheng L, Zhou L, Tao L, Zhang M, Cui J, Liu Y. Preliminary study of proteomic shift from normal to premalignant laryngeal lesions and to laryngeal squamous cell carcinoma. Acta Otolaryngol. 2009;129:774–8.PubMedCrossRef
29.
Zurück zum Zitat Cheng L, Zhou L, Tao L, Zhang M, Cui J, Li Y. SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis. J Cancer Res Clin Oncol. 2008;134:769–76.PubMedCrossRef Cheng L, Zhou L, Tao L, Zhang M, Cui J, Li Y. SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis. J Cancer Res Clin Oncol. 2008;134:769–76.PubMedCrossRef
Metadaten
Titel
Effect of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry on identifying biomarkers of laryngeal carcinoma
verfasst von
Chibo Liu
Chunqin Pan
Haibao Wang
Liang Yong
Publikationsdatum
01.12.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0216-z

Weitere Artikel der Ausgabe 6/2011

Tumor Biology 6/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.